About Oxford Immunotec Global (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780
Debt
Debt-to-Equity Ratio0.34%
Current Ratio5.37%
Quick Ratio4.92%
Price-To-Earnings
Trailing P/E Ratio-9.21
Forward P/E Ratio-13.05
P/E GrowthN/A
Sales & Book Value
Annual Sales$103.08 million
Price / Sales3.14
Cash FlowN/A
Price / CashN/A
Book Value$3.42 per share
Price / Book3.66
Profitability
EPS (Most Recent Fiscal Year)($1.36)
Net Income$-32,880,000.00
Net Margins-31.90%
Return on Equity-42.38%
Return on Assets-23.65%
Miscellaneous
Employees457
Outstanding Shares25,870,000
Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions
What is Oxford Immunotec Global's stock symbol?
Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global's earnings last quarter?
Oxford Immunotec Global (NASDAQ:OXFD) issued its earnings results on Tuesday, February, 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.02. The company had revenue of $25.03 million for the quarter, compared to analysts' expectations of $25.12 million. Oxford Immunotec Global had a negative net margin of 31.90% and a negative return on equity of 42.38%. The firm's quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.22) earnings per share. View Oxford Immunotec Global's Earnings History.
When is Oxford Immunotec Global's next earnings date?
What price target have analysts set for OXFD?
4 analysts have issued 1 year price objectives for Oxford Immunotec Global's stock. Their forecasts range from $15.00 to $21.00. On average, they anticipate Oxford Immunotec Global's share price to reach $18.75 in the next twelve months. View Analyst Ratings for Oxford Immunotec Global.
What are Wall Street analysts saying about Oxford Immunotec Global stock?
Here are some recent quotes from research analysts about Oxford Immunotec Global stock:
- 1. According to Zacks Investment Research, "Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company's first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. " (3/13/2018)
- 2. BTIG Research analysts commented, "This evening bluebird provided a 1Q update via press release (no conference call, as usual). Following an April meeting with the EMA, BLUE updated its EU regulatory strategy noting that it anticipates filing for conditional approval in non-B0/B0 patients on the basis of the ongoing Northstar and HGB-205 studies, plus data available from the ongoing Northstar-2 at the time of filing. Amount of follow up needed from Northstar and HGB-205 is TBD (data dependent and discussions with the EMA are ongoing). On the catalyst front, previously announced timelines are intact, and 2017 is looking to be a busy year for bluebird. Overall, we remain encouraged with the company’s continued progress across multiple clinical programs involving its potentially transformative gene therapy and CAR-T platforms. Maintain OW." (5/4/2017)
Who are some of Oxford Immunotec Global's key competitors?
Some companies that are related to Oxford Immunotec Global include Endocyte (ECYT), Novavax (NVAX), New England Nuclear (LNTH), STAAR Surgical (STAA), Hanger (HNGR), Jounce Therapeutics (JNCE), Mesa Laboratories (MLAB), Addus HomeCare (ADUS), Tactile Systems Technology (TCMD), Lannett (LCI), Reata Pharmaceuticals (RETA), Meridian Bioscience (VIVO), BeyondSpring (BYSI), Rhythm Pharmaceuticals (RYTM), Heska (HSKA), Ziopharm Oncology (ZIOP), Oxford BioMedica (OXBDF) and AC Immune (ACIU).
Who are Oxford Immunotec Global's key executives?
Oxford Immunotec Global's management team includes the folowing people:
- Richard A. Sandberg, Independent Chairman of the Board (Age 74)
- Peter James Wrighton-Smith Ph.D., Chief Executive Officer, Director (Age 42)
- Richard M. Altieri, Chief Financial Officer (Age 57)
- Stefan C. Linn, Chief Operating Officer (Age 51)
- Peter Edwardson Ph.D., Senior Vice President & Head of Blood Screening (Age 52)
- Elizabeth M. Keiley, Vice President, General Counsel (Age 51)
- Richard J. Wenstrup M.D., Chief Medical Officer (Age 65)
- Ronald A. Andrews Jr., Director (Age 57)
- Patrick J. Balthrop Sr., Director (Age 60)
- Mark Klausner, Director
Has Oxford Immunotec Global been receiving favorable news coverage?
Media coverage about OXFD stock has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Oxford Immunotec Global earned a media sentiment score of 0.20 on Accern's scale. They also gave media headlines about the company an impact score of 45.85 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Oxford Immunotec Global?
Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global's stock price today?
One share of OXFD stock can currently be purchased for approximately $12.53.
How big of a company is Oxford Immunotec Global?
Oxford Immunotec Global has a market capitalization of $334.78 million and generates $103.08 million in revenue each year. The company earns $-32,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Oxford Immunotec Global employs 457 workers across the globe.
How can I contact Oxford Immunotec Global?
Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]
MarketBeat Community Rating for Oxford Immunotec Global (OXFD)
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Oxford Immunotec Global (NASDAQ:OXFD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Oxford Immunotec Global (NASDAQ OXFD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.11%
Institutional Ownership Percentage: 93.31%
Oxford Immunotec Global (NASDAQ OXFD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/16/2018 | Richard A Sandberg | Director | Sell | 3,000 | $12.01 | $36,030.00 | |  |
| 11/1/2017 | Richard A Sandberg | Director | Sell | 3,000 | $13.35 | $40,050.00 | 17,778 | |
| 10/2/2017 | Peter Wrighton-Smith | CEO | Sell | 55,000 | $16.78 | $922,900.00 | | |
| 9/1/2017 | Richard A Sandberg | Director | Sell | 3,000 | $15.82 | $47,460.00 | 18,000 | |
| 8/15/2017 | Peter Edwardson | COO | Sell | 9,739 | $16.14 | $157,187.46 | 92,905 | |
| 8/7/2017 | Peter Edwardson | COO | Sell | 22,371 | $17.70 | $395,966.70 | 102,644 | |
| 7/6/2017 | Peter Wrighton-Smith | CEO | Sell | 27,168 | $15.94 | $433,057.92 | 488,836 | |
| 7/5/2017 | Peter Wrighton-Smith | CEO | Sell | 32,832 | $16.58 | $544,354.56 | 478,106 | |
| 6/28/2017 | Peter Wrighton-Smith | CEO | Sell | 30,000 | $16.06 | $481,800.00 | 491,668 | |
| 6/15/2017 | Elizabeth M Keiley | VP | Sell | 4,085 | $15.01 | $61,315.85 | 25,393 | |
| 5/15/2017 | Peter Edwardson | COO | Sell | 10,000 | $14.66 | $146,600.00 | 125,015 | |
| 5/10/2017 | Richard A Sandberg | Director | Sell | 3,000 | $14.40 | $43,200.00 | 20,174 | |
| 5/9/2017 | Jeff R Schroeder | Insider | Sell | 40,000 | $14.14 | $565,600.00 | 149,544 | |
| 4/3/2017 | Peter Wrighton-Smith | CEO | Sell | 30,000 | $15.43 | $462,900.00 | 491,668 | |
| 4/3/2017 | Richard A Sandberg | Director | Sell | 3,000 | $15.47 | $46,410.00 | 17,174 | |
| 3/20/2017 | Elizabeth M Keiley | VP | Sell | 3,000 | $16.05 | $48,150.00 | 25,429 | |
| 2/6/2017 | Peter Wrighton-Smith | CEO | Sell | 25,000 | $13.36 | $334,000.00 | 463,495 | |
| 12/16/2016 | Peter Wrighton-Smith | CEO | Sell | 7,052 | $15.07 | $106,273.64 | 450,366 | |
| 12/5/2016 | Peter Wrighton-Smith | CEO | Sell | 1,140 | $15.00 | $17,100.00 | 444,454 | |
| 12/2/2016 | Peter Wrighton-Smith | CEO | Sell | 61,808 | $15.00 | $927,120.00 | 504,122 | |
| 11/8/2016 | Richard A Sandberg | Director | Sell | 12,000 | $14.17 | $170,040.00 | 31,774 | |
| 11/18/2015 | Richard A. Sandberg | Director | Sell | 5,000 | $13.48 | $67,400.00 | 32,174 | |
| 11/17/2015 | Richard A. Sandberg | Director | Sell | 5,000 | $13.00 | $65,000.00 | 37,174 | |
| 6/16/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 41,230 | $14.30 | $589,589.00 | | |
| 6/15/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 1,529 | $14.27 | $21,818.83 | | |
| 6/12/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 31,598 | $14.27 | $450,903.46 | | |
| 6/10/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 24,649 | $14.28 | $351,987.72 | | |
| 6/9/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 13,000 | $14.26 | $185,380.00 | | |
| 6/8/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 2,662 | $14.25 | $37,933.50 | | |
| 6/3/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 36,474 | $14.29 | $521,213.46 | | |
| 6/1/2015 | Richard A Sandberg | Director | Sell | 3,000 | $14.14 | $42,420.00 | | |
| 3/23/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 53,415 | $14.49 | $773,983.35 | | |
| 3/19/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 154,319 | $14.65 | $2,260,773.35 | | |
| 1/14/2015 | Richard A Sandberg | Director | Sell | 3,000 | $14.00 | $42,000.00 | | |
| 12/5/2014 | Patricia Randall | Director | Sell | 5,000 | $12.06 | $60,300.00 | | |
(Data available from 1/1/2013 forward)
Oxford Immunotec Global (NASDAQ OXFD) News Headlines
| Source: |
|
Oxford Immunotec Global (NASDAQ:OXFD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Oxford Immunotec Global (NASDAQ:OXFD) Income Statement, Balance Sheet and Cash Flow Statement
Oxford Immunotec Global (NASDAQ OXFD) Stock Chart for Sunday, April, 22, 2018
Loading chart…
